Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa

Figures & data

Table 1. Current recombinant prophylactic treatment options for hemophilia B approved by the EMA

Classification according to half-life	Product	Fussion protein	Brand	Manufacturer
Standard	rFIX (nonacog alfa)		BeneFIX®	Pfizer
	BAX 326 (nonacog gamma)		Rixubis®	Baxalta Innovations GmbH
Extended	rIX-FP (albutrepenonacog alfa)	Albumin	Idelvion®	CSL Behring
	rFIX-Fc (eftrenonacog alfa)	Fragment crystallizable	Alprolix®	Biogen Inc
	N9-GP (nonacog beta pegol)	Polietilenglicol	Refixia®	Novo Nordisk

Figure 1. Characteristics of patients who may especially benefit from prophylactic treatment with rIX-FP and potential advantages

Figure 2. Algorithm for switching patients from FIX products to rIX-FP

PK, Pharmacokinetics*PK assessment to be performed before switching, to estimate the dose and frequency of infusion for maintaining appropriate trough levels; or two weeks after switching, to assess whether the dose and frequency of infusion are adequate.** At the discretion of the clinician.